The 2022 Nobel Prize in chemistry was awarded to Carolyn Bertozzi of Stanford University, to Morten Meldal of the University of Copenhagen, and – for the second time – to Barry Sharpless of The Scripps Research Institute “for the development of click chemistry and bioorthogonal
chemistry.”
Click chemistry, the Nobel Committee’s Olof Ramström told reporters while announcing the prize, “is almost like it sounds – it’s all about linking different molecules.”
He likened click chemistry to a seatbelt buckle, whose interlocking parts can be attached to many different materials, linking them by snapping the two parts of the buckle together.
“The problem was to find good chemical buckles,” Ramström said – chemicals that “will easily snap together, and importantly, they won’t snap with anything else.” Read More
Researchers from Enanta Pharmaceuticals Inc. presented preclinical data for the small molecule non-nucleoside respiratory syncytial virus (RSV) L-protein inhibitor, EDP-323, being developed for the treatment of RSV infection. Read More
Atopic dermatitis is the most common inflammatory skin disorder with a complex etiology. On the other hand, autophagy is an essential process by which cells break down undesired components to maintain their homeostasis. Read More
Praetego Inc. has been awarded a US$2.5 million phase II Small Business Technology Transfer (STTR) award from the National Institute on Aging (NIA) to its advance lead candidate, PTG-630, for Alzheimer's disease. Read More
Endpoint Health Inc. has announced a new precision immunology program targeting inflammation mediated by tissue factor (TF)-dependent intracellular signaling. Read More
Mirecule Inc. has entered into a strategic collaboration and exclusive license agreement with Sanofi SA to develop and commercialize a best-in-class antibody-RNA conjugate (ARC) for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Read More
Akita University and Tohoku University have described curcumin derivatives acting as β-catenin (CTNNB1) and NF-κB activation inhibitors reported to be useful for the treatment of cancer. Read More
Galecto Biotech AB has divulged new galectin-3 (LGALS3) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, fibrosis and cardiovascular, eye, metabolic, cerebrovascular and inflammatory disorders, among other disorders. Read More
Hanall Biopharma Co. Ltd. has clarified that the new FcRn inhibitor IMVT-1402, unveiled by its licensed partner Immunovant Inc. as a new development program for autoimmune diseases, is a compound discovered and developed by Hanall, HL-161ANS. Read More
Leitat Technological Center has patented 2,3-dihydro-1h-pyrrolo[3,2-b]pyridine derivatives acting as sigma non-opioid intracellular receptor 1 (SIGMAR1) and sigma intracellular receptor 2 (TMEM97) ligands reported to be useful for the treatment of pain, hyperalgesia, depression, anxiety and attention deficit hyperactivity disorder (ADHD). Read More
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has identified new histone deacetylase 1 (HDAC1) and/or HDAC3 inhibitors reported to be useful for the treatment of cancer. Read More
Hereditary tyrosinemia type 1 (HT1) is an inborn error of metabolism caused by deficiency of the fumarylacetoacetate hydrolase (FAH) enzyme and people with it are unable to metabolize the amino acid tyrosine. Toxic metabolites accumulate in the liver leading to severe oxidative damage. Read More
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has synthesized new heterocyclic RAF kinase and/or Ras GTPases inhibitors reported to be useful for the treatment of cancer. Read More
